why choose us

Clinical Trials Search

Showing 9,110 of 132,656 result(s)
Cranial Electrotherapy Stimulation and Acute Stress

Status: Completed

Condition: Anxiety State

Interventions: Active CES group will receive a minimum of 250µA and up to 500µA depending on thresholding, once daily for 20 days (over the course of 4~6 weeks), 20

Date: 2023-08-18

Associations Between the Microbiome, Skeletal Muscle Perfusion, and Fitness Status

Status: Completed

Condition: Heart Failure, Systolic

Interventions:

Date: 2023-08-18

XG005 for Pain Control in Subjects Undergoing Bunionectomy

Status: Completed

Condition: Acute Pain

Interventions: Subjects will receive XG005 prior to surgery and every 12 hours for 72 hours.

Date: 2023-08-18

A Study of Blood Pressure Control During Cancer Treatment

Status: Completed

Condition: Breast Cancer

Interventions:

One or more of the following medications may be used in both randomization groups to achieve SBP goals:

  • Angiotensin converting enzyme in

    Date: 2023-08-18

Two Implementation Strategies for the Collection of Electronic Patient-Reported Outcomes Among Patients With Multiple Myeloma

Status: Completed

Condition: Multiple Myeloma

Interventions: Receive text notification

Date: 2023-08-18

Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors

Status: Completed

Condition: Solid Tumor

Interventions: Every 2 weeks

Date: 2023-08-17

Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer

Status: NOT_YET_RECRUITING

Condition: MSI-H Colorectal Cancer

Interventions: A multi-kinase inhibitor that targets several receptor tyrosine kinases including vascular endothelial growth factor receptor (VEGFR), which may also

Date: 2023-08-17

In Situ Comparison of the Remineralization Potential of Optimized Fluoride Dentifrice With Control Fluoride Dentifrice

Status: Completed

Condition: Caries

Interventions: • Each subject will use this product during one of the three treatment periods in the crossover study design.

Date: 2023-08-17

A Study of Avutometinib and Defactinib in People With Thyroid Cancer

Status: Completed

Condition: Thyroid Cancer

Interventions: Avutometinib 3.2 mg twice weekly 3 weeks on;1 week off

Date: 2023-08-17